View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Contents<br />
Chapter 1: Introduction and objectives<br />
1.1 General introduction 13<br />
1.2 Ovarian physiology 18<br />
1.1.1. Ovarian development 18<br />
1.1.2. Early follicle development 18<br />
1.1.3. Advanced follicle development: the “threshold/window” concept 19<br />
1.3 Disturbed folliculogenesis 20<br />
1.4 Assisted reproduction 22<br />
1.4.1. Management of subfertility 22<br />
1.4.2. Ovulation induction 22<br />
1.4.3. Ovarian (hyper)stimulation 23<br />
1.5 Study objectives 24<br />
Chapter 2: Follicle dynamics and endocrine aspects after intervention in the<br />
normal menstrual cycle<br />
2.1 Low-dose exogenous FSH initiated during the early, mid or late follicular<br />
phase can induce multiple dominant follicle development<br />
2.1.1. Introduction 29<br />
2.1.2. Materials and methods 30<br />
2.1.3. Results 31<br />
2.1.4. Discussion 39<br />
2.2 Relationship between inhibin A and B, oestradiol and follicle growth<br />
dynamics during ovarian stimulation in normo-ovulatory women<br />
42<br />
2.2.1. Introduction 42<br />
2.2.2. Materials and methods 43<br />
2.2.3. Results 45<br />
2.2.4. Discussion 49<br />
Chapter 3: Mild ovarian stimulation for assisted reproduction<br />
3.1 Introduction 53<br />
3.2 A randomized comparison of two stimulation protocols with GnRH<br />
antagonist co-treatment for in vitro fertilization commencing recombinant<br />
FSH on cycle day 2 or 5 with the standard long GnRH agonist protocol<br />
54<br />
3.2.1. Introduction 54<br />
3.2.2. Materials and methods 55<br />
3.2.3. Results 58<br />
3.2.4. Discussion 63<br />
Chapter 4: Alternative approaches to disturbed follicle growth<br />
4.1 Introduction 69<br />
4.2 LH suppression following different doses of the GnRH antagonist<br />
ganirelix (Orgalutran ® 69<br />
) in polycystic ovary syndrome